Security
Vaxcyte, Inc. Common Stock · PCVX
PCVXNASDAQCommon stockCurrentCIK 1649094Updated Oct 3, 2026
Name history
SutroVax, Inc. · through Apr 3, 2020
PCVX price & chart
Loading TradingView…
NASDAQ:PCVX on TradingView ↗About the company
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. VAX-31, a 31-valent PCV candidate advancing to a Phase 3 adult clinical program and currently being evaluated in a Phase 2 infant clinical program, is being developed for the prevention of IPD in adults and infants and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is currently being evaluated in a Phase 2 infant study. Both VAX-31 and VAX-24 are designed to improve upon the standard-of-care PCVs by covering the serotypes in circulation that are responsible for a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains that are currently contained through continued vaccination practice. Vaxcyte is re-engineering the way highly complex vaccines are made through modern synth…
In the news
Vaxcyte to Participate in Upcoming Investor Conferences ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 3,002,717,000Source | 3,511,318,000Source | 1,407,917,000Source | 1,006,178,000Source |
| Property, Plant and Equipment, NetUSD | 257,370,000Source | 198,045,000Source | 79,626,000Source | 10,360,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 173,959,000Source | 387,878,000Source | 397,451,000Source | 834,657,000Source |
| Assets, CurrentUSD | 1,627,361,000Source | 1,787,985,000Source | 1,095,954,000Source | 942,555,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 66,402,000Source | 40,777,000Source | 15,727,000Source | 11,179,000Source |
| Operating Lease, Right-of-Use AssetUSD | 116,009,000Source | 72,102,000Source | 30,997,000Source | 21,288,000Source |
| Other Assets, NoncurrentUSD | 118,847,000Source | 64,359,000Source | 37,562,000Source | 4,555,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 317,207,000Source | 205,499,000Source | 167,449,000Source | 52,565,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 134,000Source | 128,000Source | 98,000Source | 82,000Source |
| Retained Earnings (Accumulated Deficit)USD | -2,154,947,000Source | -1,388,319,000Source | -924,392,000Source | -522,126,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 1,587,000Source | -3,873,000Source | 179,000Source | -361,000Source |
| Stockholders' Equity Attributable to ParentUSD | 2,685,510,000Source | 3,305,819,000Source | 1,240,468,000Source | 953,613,000Source |
| Additional Paid in Capital, Common StockUSD | 4,838,736,000Source | 4,697,883,000Source | 2,164,583,000Source | 1,476,018,000Source |
| Liabilities and EquityUSD | 3,002,717,000Source | 3,511,318,000Source | 1,407,917,000Source | 1,006,178,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 205,750,000Source | 140,180,000Source | 145,338,000Source | 40,525,000Source |
| Operating Lease, Liability, CurrentUSD | 6,124,000Source | 5,891,000Source | 7,113,000Source | 5,910,000Source |
| Accounts Payable, CurrentUSD | 70,904,000Source | 48,452,000Source | 14,587,000Source | 9,795,000Source |
| Operating Lease, Liability, NoncurrentUSD | 111,357,000Source | 65,219,000Source | 22,111,000Source | 12,031,000Source |
| Other Liabilities, NoncurrentUSD | 100,000Source | 100,000Source | 0Source | 9,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 31,068,000Source | 29,123,000Source | 59,815,000Source | 15,375,000Source |
| Short-term InvestmentsUSD | 1,387,000,000Source | 1,359,330,000Source | 682,776,000Source | 96,719,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -766,628,000Source | -463,927,000Source | -402,266,000Source | -223,485,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 16,396,000Source | 7,003,000Source | 3,156,000Source | 2,577,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 138,845,000Source | 84,822,000Source | 48,760,000Source | 23,650,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 19,906,000Source | 34,584,000Source | 11,225,000Source | 2,896,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -655,577,000Source | -452,627,000Source | -296,790,000Source | -170,597,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 437,354,000Source | -2,005,666,000Source | -773,311,000Source | 74,585,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 13,713,000Source | 22,427,000Source | 16,062,000Source | 5,848,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 10,991,000Source | 14,292,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 2,014,000Source | 2,448,508,000Source | 639,813,000Source | 861,547,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -213,770,000Source | -9,359,000Source | -436,974,000Source | 765,672,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 175,425,000Source | 389,195,000Source | 398,554,000Source | 835,528,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | 0Source | 2,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 2,439,000Source | 426,000Source | -6,686,000Source | 137,000Source |
| Additional Financial Items | ||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -1,897,000Source | -1,470,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | 0Source | -44,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | 0Source | -44,000Source |
| General and Administrative ExpenseUSD | 129,369,000Source | 92,902,000Source | 60,700,000Source | 39,810,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| InterestExpenseNonoperatingUSD | — | 0Source | — | — |
| Investment Income, InterestUSD | 119,718,000Source | 109,994,000Source | 62,907,000Source | 8,356,000Source |
| Net Income (Loss) Attributable to ParentUSD | -766,628,000Source | -463,927,000Source | -402,266,000Source | -223,485,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -766,628,000Source | -463,927,000Source | -402,266,000Source | -223,485,000Source |
| Nonoperating Income (Expense)USD | 157,047,000Source | — | — | — |
| Operating ExpensesUSD | 923,675,000Source | 569,546,000Source | 468,041,000Source | 232,256,000Source |
| Operating Lease, ExpenseUSD | 15,400,000Source | 11,500,000Source | 8,500,000Source | 7,900,000Source |
| Other Nonoperating Income (Expense)USD | 37,329,000Source | 105,619,000Source | 65,775,000Source | 8,771,000Source |
| Proceeds from Issuance of Common StockUSD | — | 195,943,000Source | 90,741,000Source | 97,299,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 1,531,136,000Source | 1,133,235,000Source | 611,876,000Source | 168,691,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | 5,608,000Source | 4,895,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -923,675,000Source | -569,546,000Source | -468,041,000Source | -232,256,000Source |
| Other Nonoperating Income (Expense)USD | 37,329,000Source | 105,619,000Source | 65,775,000Source | 8,771,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -766,628,000Source | -463,927,000Source | -402,266,000Source | -223,485,000Source |
| Earnings Per Share, BasicUSD per share | -5.63Source | -3.8Source | -4.14Source | -3.44Source |
| Earnings Per Share, DilutedUSD per share | -5.63Source | -3.8Source | -4.14Source | -3.44Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 136,089,506Source | 121,997,348Source | 97,157,690Source | 64,877,988Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 136,089,506Source | 121,997,348Source | 97,157,690Source | 64,877,988Source |
| Interest Expense (non-operating)USD | — | 0Source | — | — |
| Additional Financial Items | ||||
| Common Stock, Dividends, Per Share, DeclaredUSD per share | 0Source | 0Source | 0Source | 0Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 16,400,000Source | 7,000,000Source | 3,200,000Source | 2,600,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -1,897,000Source | -1,470,000Source |
| General and Administrative ExpenseUSD | 129,369,000Source | 92,902,000Source | 60,700,000Source | 39,810,000Source |
| Interest ExpenseUSD | — | — | 0Source | 2,000Source |
| Investment Income, InterestUSD | 119,718,000Source | 109,994,000Source | 62,907,000Source | 8,356,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -766,628,000Source | -463,927,000Source | -402,266,000Source | -223,485,000Source |
| Nonoperating Income (Expense)USD | 157,047,000Source | — | — | — |
| Operating ExpensesUSD | 923,675,000Source | 569,546,000Source | 468,041,000Source | 232,256,000Source |
| Operating Lease, ExpenseUSD | 15,400,000Source | 11,500,000Source | 8,500,000Source | 7,900,000Source |
| Other IncomeUSD | — | -4,375,000Source | — | — |
| Preferred Stock, Dividends Per Share, DeclaredUSD per share | 0Source | 0Source | 0Source | — |
| Research and Development ExpenseUSD | 794,306,000Source | 476,644,000Source | 332,341,000Source | 169,451,000Source |
Filing attachments
d848914dex991.htm · 8-K · 2025-03-31
EX-99.1 2 d848914dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study - At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) - - At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization Series; Topline Results Also Include Interim Booster Dose IgG Data Showing Robust Memory Response…
Read attachment ↗d848914dex992.htm · 8-K · 2025-03-31
EX-99.2 3 d848914dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 VAX-24 Infant Phase 2 Dose- Finding Study Topline Results March 31, 2025 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements related to the ability of Vaxcyte’s vaccine candidates and platform to achieve the broadest coverage of any infant pneumococcal conjugate vaccine …
Read attachment ↗